Paul Reider
Equibles does not estimate personal net worth.
About Paul Reider
Coherus Oncology, Inc. reported in an 8-K filed April 22, 2025 that Paul Reider resigned as Chief Commercial Officer, effective April 30, 2025. Paul Reider has spoken on 1 earnings call across 1 company, most recently for Coherus Oncology, Inc. on March 10, 2025. The companies whose calls Paul Reider spoke on are classified in the Healthcare sector.
“Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities following the completion of the Company’s divestiture of its UDENYCA franchise, the Company’s last biosimilar product.”
Paul Reider on recent calls
“We'll now review brand-specific upgrades, starting with UDENYCA. UDENYCA net product sales for Q4 were $46.3 million, an increase of 28% compared to $36.2 million for Q4 2023.”
Affiliation history
-
Coherus Oncology, Inc. (CHRS)
Proxy statement
Start not stated–2025-04-30